| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 05/30/2000 | US6069293 Healing pack and applicator and method |
| 05/30/2000 | US6069283 Illudin analogs useful as antitumor agents |
| 05/30/2000 | US6069165 Administering to the patient suffering from dysthymia, psychoses, paranoid and productive schizophrenias, acute delirous psychoses, an effective amount of amisulpride or salts |
| 05/30/2000 | US6069139 Method and composition for prophulaxis and treatment of retinal diseases |
| 05/30/2000 | US6069135 Use of hyaluronic acid or its derivatives to enhance delivery of therapeutic agents |
| 05/30/2000 | US6069134 Methods and compositions comprising DNA damaging agents and p53 |
| 05/30/2000 | US6069129 Elastin derived composition and method of using same |
| 05/30/2000 | US6068983 Introducing into cells a dna molecule coding for an fc receptor which is then expressed for increased phagocytic activity; combating infection and/or modulating immune complex disease |
| 05/30/2000 | US6068981 Marking of orally ingested products |
| 05/30/2000 | US6068860 For topical administration comprising foscarnet and an antiinflammatory glucocorticoid, with a carrier based on galactolipids comprising digalactosyldiacylglycerols, and a polar solvent; treating herpes infections |
| 05/30/2000 | US6068859 Controlled-release dosage forms of Azithromycin |
| 05/30/2000 | US6068858 Methods of making nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers |
| 05/30/2000 | US6068857 Microparticles containing active ingredients, agents containing these microparticles, their use for ultrasound-controlled release of active ingredients, as well as a process for their production |
| 05/30/2000 | US6068856 Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole |
| 05/30/2000 | US6068855 Mechanically working a mixture of a drug and a hydrophobic and/or hydrophilic fusible carrier in a high speed mixer so as to form an agglomerates, extruding the agglomerate to form an extrudate |
| 05/30/2000 | US6068854 Sol-controlled thermocolloid matrix based on gelatin for oral sustained-release form |
| 05/30/2000 | US6068853 Temporally controlled drug delivery systems |
| 05/30/2000 | US6068851 Formulation for use in the prevention of pathogen induced diseases including HIV and HSV |
| 05/30/2000 | US6068850 A stable aqueous formulation of a peptide related compound comprising atleast one peptide compoun and water, wherein the formulation is stable at 37 degree c. atleast 2 months, useful in an implantable drug delivery device |
| 05/30/2000 | US6068833 Methods and compositions for treating pulmonary disorders using optically pure (R,R) formoterol |
| 05/30/2000 | US6068832 Chlorofluorocarbon-free mometasone furoate aerosol formulations |
| 05/30/2000 | US6068600 Use of hollow microcapsules |
| 05/30/2000 | CA2190628C An implantable containment apparatus for a therapeutical device and method for loading and reloading the device therein |
| 05/30/2000 | CA2171844C Sustained release formulations for 24 hour release of metoprolol |
| 05/30/2000 | CA2144407C Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
| 05/30/2000 | CA2143497C Self-tan cosmetic compositions containing dihydroxyacetone; process for preparing the same and their use |
| 05/30/2000 | CA2086094C Vaccine compositions containing liposomes |
| 05/30/2000 | CA2083333C High dosage topical forms of collagenase |
| 05/30/2000 | CA2050067C Controlled drug release composition |
| 05/30/2000 | CA2014889C Intra-rectal pharmaceutical foam compositions |
| 05/30/2000 | CA2002472C Liquid oral formulation |
| 05/30/2000 | CA2001969C Polysiloxane-polyurethanes and contact lenses thereof |
| 05/25/2000 | WO2000029620A1 Methods of facilitating vascular growth |
| 05/25/2000 | WO2000029601A1 A method for depopulating of vertebrate testis and for generation of transgenic species |
| 05/25/2000 | WO2000029588A1 Lysozyme fusion proteins in infections |
| 05/25/2000 | WO2000029477A1 Poly(alpha-1,4-d-glucan) and thermoplastic polymer mixtures containing the same |
| 05/25/2000 | WO2000029464A1 Novel membrane or matrix for controlling drug permeation |
| 05/25/2000 | WO2000029449A1 Biopolymer salts with low endotoxin levels, biopolymer compositions thereof and methods of making the same |
| 05/25/2000 | WO2000029206A1 Monodisperse preparations useful with implanted devices |
| 05/25/2000 | WO2000029205A1 Apparatus and method for manufacturing moulded products |
| 05/25/2000 | WO2000029103A1 Method and apparatus for liposome production |
| 05/25/2000 | WO2000029027A1 Antiviral formulations comprising propylene glycol and an isopropyl alkanoic acid ester |
| 05/25/2000 | WO2000029026A1 Suppositories |
| 05/25/2000 | WO2000029025A1 Stable amorphous amifostine compositions and methods for the preparation and use of same |
| 05/25/2000 | WO2000029024A1 Formulation of adenovirus for gene therapy |
| 05/25/2000 | WO2000029021A1 Percutaneously administrable preparations containing cerebral function activators |
| 05/25/2000 | WO2000029020A1 Anti-icam-r antibody-induced apoptosis |
| 05/25/2000 | WO2000029018A1 Combined vaccine against both hav and measle virus and method of producing it |
| 05/25/2000 | WO2000029013A1 Stable aqueous insulin preparations without phenol and cresol |
| 05/25/2000 | WO2000028998A1 Liquid ophthalmic preparations |
| 05/25/2000 | WO2000028990A1 Pharmaceutical composition for modified release insulin sensitiser |
| 05/25/2000 | WO2000028989A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/25/2000 | WO2000028979A1 Dry powder for inhalation |
| 05/25/2000 | WO2000028977A1 Antioxidant gel for gingival conditions |
| 05/25/2000 | WO2000028976A1 Multi chamber soft capsules and method of making the same |
| 05/25/2000 | WO2000028975A2 Improved chemical process and pharmaceutical formulation |
| 05/25/2000 | WO2000028974A1 Local delivery of drugs to the colon for local treatment of colonic diseases |
| 05/25/2000 | WO2000028973A1 Process for preparing oral calcium compositions |
| 05/25/2000 | WO2000028972A2 Nanocapsules and method of production thereof |
| 05/25/2000 | WO2000028971A1 Nano-emulsion of 5-aminolevulinic acid |
| 05/25/2000 | WO2000028970A1 Vaginally administrable progesterone-containing tablets and method for preparing same |
| 05/25/2000 | WO2000028969A2 Methods for preparing coated drug particles and pharmaceutical formulations thereof |
| 05/25/2000 | WO2000028968A1 Drug delivery device, especially for the delivery of progestins and estrogens |
| 05/25/2000 | WO2000028967A1 Drug delivery device, especially for the delivery of androgens |
| 05/25/2000 | WO2000028952A1 Flavour blend for masking unpleasant taste of zinc compounds |
| 05/25/2000 | WO2000028942A1 Process for the manufacture of liquid filled capsules |
| 05/25/2000 | WO2000028821A1 Therapeutic anti-fungal nail preparation |
| 05/25/2000 | WO2000021528A8 Use of ophthalmic composition comprising vitamin a and vitamin e |
| 05/25/2000 | WO2000018254A3 Method of protecting heat- or oxygen-labile compounds to preserve activity and bioavailability |
| 05/25/2000 | WO2000016762A3 Method for reducing nicotine dependency |
| 05/25/2000 | WO2000007603A9 End modified thermal responsive hydrogels |
| 05/25/2000 | WO2000004884A9 Pharmaceutical preparations for the topical treatment of mucocutaneous herpes infections and herpetic keratitis of the eye |
| 05/25/2000 | WO1998049350A8 In vivo use of recombinagenic oligonucleobases to correct genetic lesions in hepatocytes |
| 05/25/2000 | DE19937794A1 Composition useful for promoting wound healing comprises eugenol and polyphenols |
| 05/25/2000 | DE19854139A1 Antiprotozoal composition useful for e.g. treating malaria and sleeping sickness comprises diminazene diaceturate, glycerol and N-methylpyrrolidone |
| 05/25/2000 | DE19853985A1 Producing solid dosage form, using molding calender of two cylinders with specific surface structures, avoids problems of misalignment of upper and lower halves of the product |
| 05/25/2000 | DE19853937A1 Composition useful for treating e.g. malaria, babesiosis and trypanosomiasis comprises diminazene diaceturate and procaine |
| 05/25/2000 | DE19853487A1 Use of dialkyl fumarate for treating transplant rejection and autoimmune disease |
| 05/25/2000 | DE19853286A1 Electrically controllable laboratory gel-permeation device which can be used for laboratory or medical dosing of soluble substances |
| 05/25/2000 | CA2352830A1 Biopolymer salts with low endotoxin levels, biopolymer compositions thereof and methods of making the same |
| 05/25/2000 | CA2351711A1 Nanocapsules and method of production thereof |
| 05/25/2000 | CA2351091A1 Novel membrane or matrix for controlling drug permeation |
| 05/25/2000 | CA2351064A1 Drug delivery device, especially for the delivery of androgens |
| 05/25/2000 | CA2351058A1 Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent |
| 05/25/2000 | CA2350890A1 Aqueous compositions for long-term stable storage of adenovirus particles including uses and methods for preparing same |
| 05/25/2000 | CA2350450A1 Flavour blend for masking unpleasant taste of zinc compounds |
| 05/25/2000 | CA2349837A1 Lysozyme fusion proteins in infections |
| 05/25/2000 | CA2349581A1 Anti-icam-r antibody-induced apoptosis |
| 05/25/2000 | CA2343946A1 Poly(alpha-1,4-d-glucan) and thermoplastic polymer mixtures containing the same |
| 05/25/2000 | CA2340468A1 Methods of facilitating vascular growth |
| 05/24/2000 | EP1002547A1 Hydrosoluble hedgehog protein in ionic complex and pharmaceutical use thereof |
| 05/24/2000 | EP1002531A1 A water-miscible composition of non-steroidal antiinflammatory drugs |
| 05/24/2000 | EP1002530A2 Delivery systems for active ingredients comprising a salicylic acid derivative composition on a film structure and their use |
| 05/24/2000 | EP1002529A1 Sustained-release preparation containing a metal salt of a peptide |
| 05/24/2000 | EP1002073A2 Cell activation process and reagents therefor |
| 05/24/2000 | EP1002065A1 Nanocrystalline formulations of human immunodeficiency virus (hiv) protease inhibitors using cellulosic surface stabilizers and methods of making such formulations |
| 05/24/2000 | EP1002064A1 A modified polypeptide |
| 05/24/2000 | EP1001986A2 Pharmaceuticals for modulating hormone responsiveness |
| 05/24/2000 | EP1001814A1 Controlled release microencapsulated ngf formulation |
| 05/24/2000 | EP1001813A1 Pharmaceutical formulations containing voriconazole |